At Boreal, we are committed to improving cancer patient care through development of technologies for blood-based detection and monitoring of circulating tumor DNA.

from http://www.borealgenomics.com/about-boreal/our-story/

Research Grants 3 show all


$406.9K
2008

$366.2K
2009

$25.8K
2011

Patents 29show all

  • 11
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 4
    B03C - Magnetic or electrostatic separation of solid materials from solid materials or fluids
  • 4
    C12N - Microorganisms or enzymes
  • 3
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 1
    B01D - Separation
  • 1
    B01L - Chemical or physical laboratory apparatus for general use
  • 1
    B62D - Motor vehicles
  • 1
    F15B - Systems acting by means of fluids in general

Clinical Trials 1show all

1N/A

SEC Filings show all


2
D

Contact Information

Vancouver, BC
Canada

SEC Form D Funding Events

DateOfferedSoldType
2013-10-11$17,999,997$17,999,997Equity
2010-12-16$6,499,999$6,499,999Equity

Key Executives

  • Andre Marziali
    Executive Officer, Director
  • David Broemling
    Executive Officer
  • Nicholas Naclerio
    Director
  • Thomas Willis
    Director
  • Keith Crandall
    Director
  • Caley Castelein
    Director
  • Nitin Sood
    Executive Officer, Director
  • Andrea Marziali
    Executive Officer, Director
  • David Broemeling
    Executive Officer
  • Keith Crandell
    Director